Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Edd

Jon Edd, Berkeley, CA US

Patent application numberDescriptionPublished
20090326436ELECTROPORATION TO DELIVER CHEMOTHERAPEUTICS AND ENHANCE TUMOR REGRESSION - A method is disclosed for disrupting capillary blood flow and trapping materials such as chemotherapeutic agents in undesirable tissue, including cells of a cancerous or non-cancerous tumor. The method involves the placement of electrodes into or near the vicinity of capillary vessels supplying blood to capillaries in the undesirable tissue, and application of electrical pulses causing capillary blood flow disruption. In some cases, the electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body's immune system. The process may further comprise monitoring blood flow and/or infusion of a material such as a chemotherapeutic agent or marker into the blood.12-31-2009

Jon Edd, Arlington, MA US

Patent application numberDescriptionPublished
20090014360SYSTEMS AND METHODS FOR PARTICLE FOCUSING IN MICROCHANNELS - Various systems, methods, and devices are provided for focusing particles suspended within a moving fluid into one or more localized stream lines. The system can include a substrate and at least one channel provided on the substrate having an inlet and an outlet. The system can further include a fluid moving along the channel in a laminar flow having suspended particles and a pumping element driving the laminar flow of the fluid. The fluid, the channel, and the pumping element can be configured to cause inertial forces to act on the particles and to focus the particles into one or more stream lines.01-15-2009
20090305224Methods for the Cryopreservation of Mammalian Cells - The present invention features novel methods for the cryopreservation of mammalian cell that combine the advantages of the slow-freezing and vitrification approaches while avoiding their shortcomings. Generally, the methods include the use of a capillary tube made of a thermally conductive wall material and a thin wall such that the ratio of the thermal conductivity of the wall material to the wall thickness is at least 1,000-500,000. The solution is then exposed to temperatures equal to or less than −80° C. and the vitrification solution containing the mammalian cells is cooled at a rate equal to or greater than 30,000-100,000,000° C./minute. The exposure of the capillary tube with a thermally conductive and thin wall allows for vitrification of the solution in the absence of ice formation. Cryoprotectants can also be added to the vitrification solution to further prevent ice formation.12-10-2009

Jon F. Edd, Arlington, MA US

Patent application numberDescriptionPublished
20100021984Microfluidic Droplet Encapsulation - Microfluidic devices and methods for the encapsulation of particles within liquid droplets are disclosed. The new methods and devices form 1-100 picoliter-size monodisperse droplets containing the particles, such as single cells, encapsulated in individual liquid droplets. The particles can be encapsulated in droplets of a fluid by passing a fluid containing the particles through a high aspect-ratio microchannel to order the particles in the fluid, followed by forming the fluid into droplets. The resulting fraction of the liquid droplets with a single particle (e.g., a cell) is higher than the corresponding fraction of single-particle liquid droplets predicted by Poisson statistics.01-28-2010

Jon Francis Edd, Berkeley, CA US

Patent application numberDescriptionPublished
20080269586ELECTROPORATION TO INTERRUPT BLOOD FLOW - A method for disrupting blood flow to undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of vessels supplying blood to the undesirable tissue and through the application of electrical pulses causing blood flow disruption. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The process may further comprise monitoring blood flow and/or infusion of a material such as a chemotherapeutic agent or marker into the blood.10-30-2008